234 related articles for article (PubMed ID: 16556484)
1. FRA1E common fragile site breaks map within a 370kilobase pair region and disrupt the dihydropyrimidine dehydrogenase gene (DPYD).
Hormozian F; Schmitt JG; Sagulenko E; Schwab M; Savelyeva L
Cancer Lett; 2007 Feb; 246(1-2):82-91. PubMed ID: 16556484
[TBL] [Abstract][Full Text] [Related]
2. Novel aphidicolin-inducible common fragile site FRA9G maps to 9p22.2, within the C9orf39 gene.
Sawińska M; Schmitt JG; Sagulenko E; Westermann F; Schwab M; Savelyeva L
Genes Chromosomes Cancer; 2007 Nov; 46(11):991-9. PubMed ID: 17668870
[TBL] [Abstract][Full Text] [Related]
3. Lack of large intragenic rearrangements in dihydropyrimidine dehydrogenase (DPYD) gene in fluoropyrimidine-treated patients with high-grade toxicity.
Ticha I; Kleiblova P; Fidlerova J; Novotny J; Pohlreich P; Kleibl Z
Cancer Chemother Pharmacol; 2009 Aug; 64(3):615-8. PubMed ID: 19288105
[TBL] [Abstract][Full Text] [Related]
4. Positions of chromosome 3p14.2 fragile sites (FRA3B) within the FHIT gene.
Zimonjic DB; Druck T; Ohta M; Kastury K; Croce CM; Popescu NC; Huebner K
Cancer Res; 1997 Mar; 57(6):1166-70. PubMed ID: 9067288
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the human dihydropyrimidine dehydrogenase gene.
Wei X; Elizondo G; Sapone A; McLeod HL; Raunio H; Fernandez-Salguero P; Gonzalez FJ
Genomics; 1998 Aug; 51(3):391-400. PubMed ID: 9721209
[TBL] [Abstract][Full Text] [Related]
6. Dihydropyrimidine dehydrogenase deficiency caused by a novel genomic deletion c.505_513del of DPYD.
van Kuilenburg AB; Meijer J; Gökcay G; Baykal T; Rubio-Gozalbo ME; Mul AN; de Die-Smulders CE; Weber P; Mori AC; Bierau J; Fowler B; Macke K; Sass JO; Meinsma R; Hennermann JB; Miny P; Zoetekouw L; Roelofsen J; Vijzelaar R; Nicolai J; Hennekam RC
Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):509-14. PubMed ID: 20544545
[TBL] [Abstract][Full Text] [Related]
7. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.
Ezzeldin HH; Lee AM; Mattison LK; Diasio RB
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8699-705. PubMed ID: 16361556
[TBL] [Abstract][Full Text] [Related]
8. The characterization of the common fragile site FRA16D and its involvement in multiple myeloma translocations.
Krummel KA; Roberts LR; Kawakami M; Glover TW; Smith DI
Genomics; 2000 Oct; 69(1):37-46. PubMed ID: 11013073
[TBL] [Abstract][Full Text] [Related]
9. Characterization of FRA7B, a human common fragile site mapped at the 7p chromosome terminal region.
Bosco N; Pelliccia F; Rocchi A
Cancer Genet Cytogenet; 2010 Oct; 202(1):47-52. PubMed ID: 20804921
[TBL] [Abstract][Full Text] [Related]
10. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy.
Amstutz U; Farese S; Aebi S; Largiadèr CR
J Exp Clin Cancer Res; 2008 Oct; 27(1):54. PubMed ID: 18937829
[TBL] [Abstract][Full Text] [Related]
11. Common fragile site FRA11G and rare fragile site FRA11B at 11q23.3 encompass distinct genomic regions.
Fechter A; Buettel I; Kuehnel E; Savelyeva L; Schwab M
Genes Chromosomes Cancer; 2007 Jan; 46(1):98-106. PubMed ID: 17063465
[TBL] [Abstract][Full Text] [Related]
12. DPYD*2A mutation: the most common mutation associated with DPD deficiency.
Saif MW; Ezzeldin H; Vance K; Sellers S; Diasio RB
Cancer Chemother Pharmacol; 2007 Sep; 60(4):503-7. PubMed ID: 17165084
[TBL] [Abstract][Full Text] [Related]
13. Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene.
Ofverholm A; Arkblad E; Skrtic S; Albertsson P; Shubbar E; Enerbäck C
Clin Biochem; 2010 Feb; 43(3):331-4. PubMed ID: 19822137
[TBL] [Abstract][Full Text] [Related]
14. Assignment of the human dihydropyrimidine dehydrogenase gene (DPYD) to chromosome region 1p22 by fluorescence in situ hybridization.
Takai S; Fernandez-Salguero P; Kimura S; Gonzalez FJ; Yamada K
Genomics; 1994 Dec; 24(3):613-4. PubMed ID: 7713523
[No Abstract] [Full Text] [Related]
15. Identification of three novel mutations in the dihydropyrimidine dehydrogenase gene associated with altered pre-mRNA splicing or protein function.
Van Kuilenburg AB; Meinsma R; Beke E; Bobba B; Boffi P; Enns GM; Witt DR; Dobritzsch D
Biol Chem; 2005 Apr; 386(4):319-24. PubMed ID: 15899693
[TBL] [Abstract][Full Text] [Related]
16. Hemizygous deletions on chromosome 1p21.3 involving the DPYD gene in individuals with autism spectrum disorder.
Carter MT; Nikkel SM; Fernandez BA; Marshall CR; Noor A; Lionel AC; Prasad A; Pinto D; Joseph-George AM; Noakes C; Fairbrother-Davies C; Roberts W; Vincent J; Weksberg R; Scherer SW
Clin Genet; 2011 Nov; 80(5):435-43. PubMed ID: 21114665
[TBL] [Abstract][Full Text] [Related]
17. Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population.
Hsiao HH; Yang MY; Chang JG; Liu YC; Liu TC; Chang CS; Chen TP; Lin SF
Cancer Chemother Pharmacol; 2004 May; 53(5):445-51. PubMed ID: 15132136
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of the human common fragile site FRA1H.
Curatolo A; Limongi ZM; Pelliccia F; Rocchi A
Genes Chromosomes Cancer; 2007 May; 46(5):487-93. PubMed ID: 17311248
[TBL] [Abstract][Full Text] [Related]
19. A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency.
Ezzeldin H; Okamoto Y; Johnson MR; Diasio RB
Anal Biochem; 2002 Jul; 306(1):63-73. PubMed ID: 12069415
[TBL] [Abstract][Full Text] [Related]
20. Analysis of severely affected patients with dihydropyrimidine dehydrogenase deficiency reveals large intragenic rearrangements of DPYD and a de novo interstitial deletion del(1)(p13.3p21.3).
van Kuilenburg AB; Meijer J; Mul AN; Hennekam RC; Hoovers JM; de Die-Smulders CE; Weber P; Mori AC; Bierau J; Fowler B; Macke K; Sass JO; Meinsma R; Hennermann JB; Miny P; Zoetekouw L; Vijzelaar R; Nicolai J; Ylstra B; Rubio-Gozalbo ME
Hum Genet; 2009 Jun; 125(5-6):581-90. PubMed ID: 19296131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
